AGÕæÈ˹ٷ½

STOCK TITAN

[6-K] PainReform Ltd. Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary

PainReform Ltd. completed a strategic investment in LayerBio to enter the global cataract surgery market, described in the filing as a $9 billion opportunity, via a non-opiate, non-steroidal postoperative NSAID drug delivery system. The report attaches the press release as Exhibit 99.1 and states the first paragraph of that release is incorporated by reference into the company’s Form S-8 and Form F-3 registration statements.

The filing is a disclosure of the investment and the attached press release; it does not provide financial terms, clinical data, or operational results within the text of the Form 6-K itself.

PainReform Ltd. ha completato un investimento strategico in LayerBio per entrare nel mercato globale della chirurgia della cataratta, descritto nel deposito come un'opportunità di $9 billion, tramite un sistema di somministrazione postoperatorio di FANS non oppioide e non steroideo. Il rapporto allega il comunicato stampa come Exhibit 99.1 e specifica che il primo paragrafo di quel comunicato è incorporato per riferimento nelle dichiarazioni di registrazione Form S-8 e Form F-3 della società.

Il deposito costituisce la divulgazione dell'investimento e del comunicato allegato; il testo del Form 6-K non riporta termini finanziari, dati clinici né risultati operativi.

PainReform Ltd. completó una inversión estratégica en LayerBio para ingresar al mercado mundial de cirugía de cataratas, descrito en la presentación como una oportunidad de $9 billion, mediante un sistema de administración de un AINE postoperatorio no opiáceo y no esteroideo. El informe adjunta el comunicado de prensa como Exhibit 99.1 y declara que el primer párrafo de ese comunicado se incorpora por referencia en las declaraciones de registro Form S-8 y Form F-3 de la compañía.

La presentación constituye la divulgación de la inversión y del comunicado adjunto; el texto del Form 6-K no incluye términos financieros, datos clínicos ni resultados operativos.

PainReform Ltd.ëŠ� ì � 세계 백내ìž� 수술 시장ì—� 진입하기 위해 LayerBioì—� ì „ëžµì � 투ìžë¥� 완료했으ë©�, 제출서류ì—서ëŠ� ì´ë¥¼ $9 billion 규모ì� 기회ë¡� 설명하고 비오피오ì´ë“œÂ·ë¹„스테로ì´ë“œì„� 수술 í›� NSAID 약물 전달 시스í…�ì� 통해 진입한다ê³� ë°í˜”습니ë‹�. 보고서는 ë³´ë„ìžë£Œë¥� Exhibit 99.1ë¡� 첨부하고 해당 ë³´ë„ìžë£Œì� ì²� 단ë½ì� 회사ì� Form S-8 ë°� Form F-3 등ë¡ì„œë¥˜ì—� 참조ë¡� í¬í•¨í•œë‹¤ê³� 명시합니ë‹�.

ì� 제출서는 íˆ¬ìž ë°� 첨부ë� ë³´ë„ìžë£Œì� 공시ì´ë©°, Form 6-K 본문ì—는 재무 ì¡°ê±´, ìž„ìƒ ë°ì´í„� ë˜ëŠ” ìš´ì˜ ì„±ê³¼ê°€ 기재ë˜ì–´ 있지 않습니다.

PainReform Ltd. a réalisé un investissement stratégique dans LayerBio afin de pénétrer le marché mondial de la chirurgie de la cataracte, décrit dans le dépôt comme une opportunité de $9 billion, via un système d'administration post‑opératoire d'AINS non opiacé et non stéroïdien. Le rapport joint le communiqué de presse en tant qu'Exhibit 99.1 et indique que le premier paragraphe de ce communiqué est incorporé par référence dans les déclarations d'enregistrement Form S-8 et Form F-3 de la société.

Le dépôt constitue la divulgation de l'investissement et du communiqué joint ; le texte du Form 6-K lui-même ne contient ni conditions financières, ni données cliniques, ni résultats opérationnels.

PainReform Ltd. hat eine strategische Beteiligung an LayerBio abgeschlossen, um in den globalen Kataraktchirurgie-Markt einzutreten, der in der Einreichung als eine $9 billion Chance bezeichnet wird, mittels eines nicht-opioiden, nicht-steroidalen postoperativen NSAID-Abgabesystems. Der Bericht fügt die Pressemitteilung als Exhibit 99.1 bei und gibt an, dass der erste Absatz dieser Mitteilung durch Verweisung in die Registrierungsunterlagen Form S-8 und Form F-3 des Unternehmens aufgenommen wird.

Die Einreichung stellt die Offenlegung der Investition und der beigefügten Pressemitteilung dar; im Text des Form 6-K selbst werden keine finanziellen Bedingungen, klinischen Daten oder operativen Ergebnisse angegeben.

Positive
  • Completed strategic investment in LayerBio to enter the global cataract surgery market.
  • Targets a $9 billion global cataract surgery opportunity with a non-opiate, non-steroidal postoperative NSAID drug delivery system.
  • The press release is filed as Exhibit 99.1 and its first paragraph is incorporated by reference into the company’s Form S-8 and Form F-3 registration statements.
Negative
  • None.

Insights

TL;DR: Completed investment positions PainReform to access a $9B cataract surgery market via LayerBio’s postoperative NSAID delivery technology.

The filing announces a strategic investment that explicitly targets the global cataract surgery market and highlights a non-opiate, non-steroidal postoperative NSAID drug delivery system. For industry stakeholders, the material fact is the company’s entry strategy into a sizeable surgical market through an equity/strategic stake rather than an immediate product launch. The disclosure is potentially positive because it signals a directional shift into surgical drug delivery and a partnership/investment route to commercialization, but the filing lacks transaction economics, clinical status, or timelines needed to assess near-term commercial impact.

TL;DR: The Form 6-K documents a material strategic investment and incorporates a press release by reference but provides limited transactional detail.

From a disclosure and market perspective, the company has met public reporting requirements by furnishing the press release as Exhibit 99.1 and incorporating its opening paragraph into registration statements. The filing is informative about strategic direction but neutral in valuation terms because it does not include deal size, equity stake, accounting treatment, or expected timing. Investors seeking financial impact must await additional disclosures with quantitative detail.

PainReform Ltd. ha completato un investimento strategico in LayerBio per entrare nel mercato globale della chirurgia della cataratta, descritto nel deposito come un'opportunità di $9 billion, tramite un sistema di somministrazione postoperatorio di FANS non oppioide e non steroideo. Il rapporto allega il comunicato stampa come Exhibit 99.1 e specifica che il primo paragrafo di quel comunicato è incorporato per riferimento nelle dichiarazioni di registrazione Form S-8 e Form F-3 della società.

Il deposito costituisce la divulgazione dell'investimento e del comunicato allegato; il testo del Form 6-K non riporta termini finanziari, dati clinici né risultati operativi.

PainReform Ltd. completó una inversión estratégica en LayerBio para ingresar al mercado mundial de cirugía de cataratas, descrito en la presentación como una oportunidad de $9 billion, mediante un sistema de administración de un AINE postoperatorio no opiáceo y no esteroideo. El informe adjunta el comunicado de prensa como Exhibit 99.1 y declara que el primer párrafo de ese comunicado se incorpora por referencia en las declaraciones de registro Form S-8 y Form F-3 de la compañía.

La presentación constituye la divulgación de la inversión y del comunicado adjunto; el texto del Form 6-K no incluye términos financieros, datos clínicos ni resultados operativos.

PainReform Ltd.ëŠ� ì � 세계 백내ìž� 수술 시장ì—� 진입하기 위해 LayerBioì—� ì „ëžµì � 투ìžë¥� 완료했으ë©�, 제출서류ì—서ëŠ� ì´ë¥¼ $9 billion 규모ì� 기회ë¡� 설명하고 비오피오ì´ë“œÂ·ë¹„스테로ì´ë“œì„� 수술 í›� NSAID 약물 전달 시스í…�ì� 통해 진입한다ê³� ë°í˜”습니ë‹�. 보고서는 ë³´ë„ìžë£Œë¥� Exhibit 99.1ë¡� 첨부하고 해당 ë³´ë„ìžë£Œì� ì²� 단ë½ì� 회사ì� Form S-8 ë°� Form F-3 등ë¡ì„œë¥˜ì—� 참조ë¡� í¬í•¨í•œë‹¤ê³� 명시합니ë‹�.

ì� 제출서는 íˆ¬ìž ë°� 첨부ë� ë³´ë„ìžë£Œì� 공시ì´ë©°, Form 6-K 본문ì—는 재무 ì¡°ê±´, ìž„ìƒ ë°ì´í„� ë˜ëŠ” ìš´ì˜ ì„±ê³¼ê°€ 기재ë˜ì–´ 있지 않습니다.

PainReform Ltd. a réalisé un investissement stratégique dans LayerBio afin de pénétrer le marché mondial de la chirurgie de la cataracte, décrit dans le dépôt comme une opportunité de $9 billion, via un système d'administration post‑opératoire d'AINS non opiacé et non stéroïdien. Le rapport joint le communiqué de presse en tant qu'Exhibit 99.1 et indique que le premier paragraphe de ce communiqué est incorporé par référence dans les déclarations d'enregistrement Form S-8 et Form F-3 de la société.

Le dépôt constitue la divulgation de l'investissement et du communiqué joint ; le texte du Form 6-K lui-même ne contient ni conditions financières, ni données cliniques, ni résultats opérationnels.

PainReform Ltd. hat eine strategische Beteiligung an LayerBio abgeschlossen, um in den globalen Kataraktchirurgie-Markt einzutreten, der in der Einreichung als eine $9 billion Chance bezeichnet wird, mittels eines nicht-opioiden, nicht-steroidalen postoperativen NSAID-Abgabesystems. Der Bericht fügt die Pressemitteilung als Exhibit 99.1 bei und gibt an, dass der erste Absatz dieser Mitteilung durch Verweisung in die Registrierungsunterlagen Form S-8 und Form F-3 des Unternehmens aufgenommen wird.

Die Einreichung stellt die Offenlegung der Investition und der beigefügten Pressemitteilung dar; im Text des Form 6-K selbst werden keine finanziellen Bedingungen, klinischen Daten oder operativen Ergebnisse angegeben.



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
Report of Foreign Private Issuer
 
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
 
For the month of August 2025
 
Commission File Number: 001-39481
 
PainReform Ltd.
(Translation of registrant’s name into English)
 
65 Yigal Alon St., Tel Aviv 6744316
Israel
(Address of principal executive offices)
 
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F     Form 40-F


 
This first paragraph of the press release attached as Exhibit 99.1 to this Report on Form 6-K is incorporated by reference into the Company’s Registration Statements on Form S-8 (Registration No. 333-257968 and 333-265902) and the Company’s Registration Statements on Form F-3 (Registration No. 333-282264, 333-254982, 333-276485, 333-277594, 333-283655 and 333-286941), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. 
 
On August 13, 2025, PainReform Ltd. issued a press release entitled “PainReform Ltd. Completes Strategic Investment in LayerBio to Enter $9B Global Cataract Surgery Market with Breakthrough Non-Opiate, Non-Steroidal Postoperative NSAID Drug Delivery System”. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.



Exhibit Index

Exhibit No.
 
Description
 
 
 
99.1

Press Release dated August 13, 2025.



 SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
Date: August 13, 2025
PAINREFORM LTD.
 
 
 
By:
/s/ Ehud Geller
 
 
Ehud Geller
Executive Chairman of the Board and Interim Chief Executive Officer
 




FAQ

What did PainReform (PRFX) report in this Form 6-K?

The company reported it completed a strategic investment in LayerBio to enter the global cataract surgery market and attached the related press release as Exhibit 99.1.

When was the press release attached to the Form 6-K issued?

The press release attached as Exhibit 99.1 is dated August 13, 2025.

Does the filing disclose the financial terms or size of the investment?

No. The Form 6-K text provided does not include any financial terms, transaction size, or equity stake details.

Does the filing include clinical or commercial results for the LayerBio technology?

No. The Form 6-K does not provide clinical data, regulatory approvals, or commercial performance information.

How does this filing affect the company’s registration statements?

The filing states the first paragraph of the attached press release is incorporated by reference into PainReform’s Form S-8 and Form F-3 registration statements.

What market opportunity is referenced in the press release?

The press release describes the target opportunity as the $9 billion global cataract surgery market and references a postoperative NSAID drug delivery system that is non-opiate and non-steroidal.
Painreform Ltd

NASDAQ:PRFX

PRFX Rankings

PRFX Latest News

PRFX Latest SEC Filings

PRFX Stock Data

2.72M
1.81M
9.62%
2.85%
7.07%
Drug Manufacturers - Specialty & Generic
Healthcare
Israel
Tel Aviv